Norbert Arnold

List of Publications by Citations

176 papers	8,240 citations	48 h-index	85 g-index
181 ext. papers	9,741 ext. citations	6.4 avg, IF	4.6 L-index

#	Paper	IF	Citations
176	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
175	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
174	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286
173	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
172	Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Journal of Clinical Oncology*, **2009**, 27, 5887-92	2.2	241
171	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
170	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
169	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
168	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
167	Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. *International Journal of Cancer*, **2002**, 97, 472-80	7.5	188
166	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
165	Molecular and prognostic distinction between serous ovarian carcinomas of varying grade and malignant potential. *Oncogene*, **2005**, 24, 1053-65	9.2	162
164	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
163	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
162	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
161	Evaluation of SNPs in miR-146a, miR196a2 and miR-499 as low-penetrance alleles in German and Italian familial breast cancer cases. *Human Mutation*, **2010**, 31, E1052-7	4.7	138
160	Prevalence of BRCA1/2 germline mutations in 21 401 families with breast and ovarian cancer. *Journal of Medical Genetics*, **2016**, 53, 465-71	5.8	114

159	A genetic variant in the pre-miR-27a oncogene is associated with a reduced familial breast cancer risk. *Breast Cancer Research and Treatment*, **2010**, 121, 693-702	4.4	110
158	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
157	Overrepresentation of 3q and 8q material and loss of 18q material are recurrent findings in advanced human ovarian cancer. *Genes Chromosomes and Cancer*, **1996**, 16, 46-54	5	101
156	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
155	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
154	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
153	A highly sensitive, fast, and economical technique for mutation analysis in hereditary breast and ovarian cancers. *Human Mutation*, **1999**, 14, 333-9	4.7	90
152	Identification of brain- and bone-specific breast cancer metastasis genes. *Cancer Letters*, **2009**, 276, 212-20	5.9	87
151	Is the Ki-67 labelling index ready for clinical use?. *Annals of Oncology*, **2011**, 22, 500-502	10.3	83
150	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82
149	A variant affecting a putative miRNA target site in estrogen receptor (ESR) 1 is associated with breast cancer risk in premenopausal women. *Carcinogenesis*, **2009**, 30, 59-64	4.6	78
148	A Fast, Highly Sensitive and Cheap Tool for Mutation Analysis of Complex Genes. *Disease Markers*, **1999**, 15, 118-118	3.2	78
147	Decreased expression of angiogenesis antagonist EFEMP1 in sporadic breast cancer is caused by aberrant promoter methylation and points to an impact of EFEMP1 as molecular biomarker. *International Journal of Cancer*, **2009**, 124, 1727-35	7.5	77
146	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation. *Cancer*, **2001**, 91, 534-540	6.4	77
145	Identification of specific BRCA1 and BRCA2 variants by DHPLC. *Human Mutation*, **2000**, 16, 345-53	4.7	76
144	Common genetic variants and modification of penetrance of BRCA2-associated breast cancer. *PLoS Genetics*, **2010**, 6, e1001183	6	74
143	Interplay between BRCA1 and RHAMM regulates epithelial apicobasal polarization and may influence risk of breast cancer. *PLoS Biology*, **2011**, 9, e1001199	9.7	73
142	Genomic reorganization and disrupted chromosomal synteny in the siamang (Hylobates syndactylus) revealed by fluorescence in situ hybridization. *American Journal of Physical Anthropology*, **1995**, 97, 37-47	2.5	72

141	Gene panel testing of 5589 BRCA1/2-negative index patients with breast cancer in a routine diagnostic setting: results of the German Consortium for Hereditary Breast and Ovarian Cancer. *Cancer Medicine*, **2018**, 7, 1349-1358	4.8	71
140	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70
139	Role of cannabinoid receptor CB2 in HER2 pro-oncogenic signaling in breast cancer. *Journal of the National Cancer Institute*, **2015**, 107, djv077	9.7	69
138	Limited relevance of the CHEK2 gene in hereditary breast cancer. *International Journal of Cancer*, **2004**, 110, 320-5	7.5	65
137	Common breast cancer susceptibility alleles are associated with tumour subtypes in BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2011**, 13, R110	8.3	62
136	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
135	Large BRCA1 gene deletions are found in 3% of German high-risk breast cancer families. *Human Mutation*, **2004**, 24, 534	4.7	61
134	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
133	Non-radioactive labeling and detection of nucleic acids. III. Applications of the digoxigenin system. *Biological Chemistry Hoppe-Seyler*, **1990**, 371, 939-51		57
132	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Human Molecular Genetics*, **2016**, 25, 2256-2268	5.6	55
131	Large scale multifactorial likelihood quantitative analysis of BRCA1 and BRCA2 variants: An ENIGMA resource to support clinical variant classification. *Human Mutation*, **2019**, 40, 1557-1578	4.7	52
130	Mutation analysis of p53 in ovarian tumors by DHPLC. *Journal of Proteomics*, **2001**, 47, 73-81		49
129	Simian Y chromosomes: species-specific rearrangements of DAZ, RBM, and TSPY versus contiguity of PAR and SRY. *Mammalian Genome*, **1998**, 9, 226-31	3.2	48
128	BRIP1 loss-of-function mutations confer high risk for familial ovarian cancer, but not familial breast cancer. *Breast Cancer Research*, **2018**, 20, 7	8.3	47
127	SNPs in ultraconserved elements and familial breast cancer risk. *Carcinogenesis*, **2008**, 29, 351-5	4.6	47
126	Associations of genetic variants in the estrogen receptor coactivators PPARGC1A, PPARGC1B and EP300 with familial breast cancer. *Carcinogenesis*, **2006**, 27, 2201-8	4.6	47
125	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
124	Germline mutations in the PALB2 gene are population specific and occur with low frequencies in familial breast cancer. *Human Mutation*, **2011**, 32, E2176-88	4.7	45

123	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
122	Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history. *BMC Cancer*, **2018**, 18, 265	4.8	43
121	An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma. *Clinical Cancer Research*, **2007**, 13, 458-66	12.9	41
120	Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. *Carcinogenesis* , **2006**, 27, 1655-60	4.6	40
119	Comparative high-resolution mapping of human and primate chromosomes by fluorescence in situ hybridization. *Genomics*, **1993**, 18, 381-6	4.3	40
118	Progression-free survival in ovarian cancer is reflected in epigenetic DNA methylation profiles. *Oncology*, **2011**, 80, 12-20	3.6	38
117	Genomic organization and molecular characterization of a gene encoding HsPXF, a human peroxisomal farnesylated protein. *Genomics*, **1997**, 45, 200-10	4.3	38
116	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
115	The c. 5096G>A p.Arg1699Gln (R1699Q) intermediate risk variant: breast and ovarian cancer risk estimation and recommendations for clinical management from the ENIGMA consortium. *Journal of Medical Genetics*, **2018**, 55, 15-20	5.8	36
114	Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction. *PLoS ONE*, **2012**, 7, e50800	3.7	36
113	Neutrophil gelatinase-associated lipocalin (NGAL) predicts response to neoadjuvant chemotherapy and clinical outcome in primary human breast cancer. *PLoS ONE*, **2012**, 7, e45826	3.7	36
112	S3-Guideline on Diagnostics, Therapy and Follow-up of Malignant Ovarian Tumours: Short version 1.0 - AWMF registration number: 032/035OL, June 2013. *Geburtshilfe Und Frauenheilkunde*, **2013**, 73, 874-889	2	34
111	Comparative mapping of DNA probes derived from the V kappa immunoglobulin gene regions on human and great ape chromosomes by fluorescence in situ hybridization. *Genomics*, **1995**, 26, 147-50	4.3	34
110	Genetic characteristics of the human hepatic stellate cell line LX-2. *PLoS ONE*, **2013**, 8, e75692	3.7	34
109	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
108	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
107	Double heterozygosity for mutations in BRCA1 and BRCA2 in German breast cancer patients: implications on test strategies and clinical management. *Breast Cancer Research and Treatment*, **2012**, 134, 1229-39	4.4	32
106	Association of the variants CASP8 D302H and CASP10 V410I with breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2010**, 19, 2859-68	4	32

105	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
104	Genetic imbalances in precursor lesions of endometrial cancer detected by comparative genomic hybridization. *American Journal of Pathology*, **2000**, 156, 1827-33	5.8	31
103	Activation of the orphan receptor GPR55 by lysophosphatidylinositol promotes metastasis in triple-negative breast cancer. *Oncotarget*, **2016**, 7, 47565-47575	3.3	31
102	Induction of human β-defensins and psoriasin in vulvovaginal human papillomavirus-associated lesions. *Journal of Infectious Diseases*, **2011**, 204, 391-9	7	30
101	Identification of candidate tumour suppressor gene loci for Hodgkin and Reed-Sternberg cells by characterisation of homozygous deletions in classical Hodgkin lymphoma cell lines. *British Journal of Haematology*, **2008**, 142, 916-24	4.5	30
100	Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. *Endocrine-Related Cancer*, **2007**, 14, 267-77	5.7	29
99	The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. *Carcinogenesis*, **2007**, 28, 423-6	4.6	27
98	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. *American Journal of Human Genetics*, **2015**, 97, 22-34	11	26
97	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
96	GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. *British Journal of Haematology*, **2009**, 144, 317-31	4.5	26
95	Comparison of gene expression data from human and mouse breast cancers: identification of a conserved breast tumor gene set. *International Journal of Cancer*, **2007**, 121, 683-8	7.5	26
94	Mutation of an IKK phosphorylation site within the transactivation domain of REL in two patients with B-cell lymphoma enhances REL's in vitro transforming activity. *Oncogene*, **2007**, 26, 2685-94	9.2	26
93	Screening for large rearrangements of the BRCA1 gene in German breast or ovarian cancer families using semi-quantitative multiplex PCR method. *Human Mutation*, **2003**, 22, 103-4	4.7	26
92	Germline loss-of-function variants in the BARD1 gene are associated with early-onset familial breast cancer but not ovarian cancer. *Breast Cancer Research*, **2019**, 21, 55	8.3	25
91	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25
90	Association of PHB 1630 C>T and MTHFR 677 C>T polymorphisms with breast and ovarian cancer risk in BRCA1/2 mutation carriers: results from a multicenter study. *British Journal of Cancer*, **2012**, 106, 2016-24	8.7	25
89	Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer. *International Journal of Cancer*, **2014**, 135, 2352-61	7.5	24
88	High expression of crystallin Bβ represents an independent molecular marker for unfavourable ovarian cancer patient outcome and impairs TRAIL- and cisplatin-induced apoptosis in human ovarian cancer cells. *International Journal of Cancer*, **2013**, 132, 2820-32	7.5	24

87	Genetic background of different cancer cell lines influences the gene set involved in chromosome 8 mediated breast tumor suppression. *Genes Chromosomes and Cancer*, **2006**, 45, 612-27	5	24
86	An easy and reliable procedure of microdissection technique for the analysis of chromosomal breakpoints and marker chromosomes. *Chromosome Research*, **1999**, 7, 355-62	4.4	24
85	Association of Genomic Domains in and with Prostate Cancer Risk and Aggressiveness. *Cancer Research*, **2020**, 80, 624-638	10.1	22
84	Low-risk variants FGFR2, TNRC9 and LSP1 in German familial breast cancer patients. *International Journal of Cancer*, **2010**, 126, 2858-62	7.5	22
83	Reverse painting of microdissected chromosome 19 markers in ovarian carcinoma identifies a complex rearrangement map. *Genes Chromosomes and Cancer*, **2009**, 48, 184-93	5	21
82	Common variants of the BRCA1 wild-type allele modify the risk of breast cancer in BRCA1 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 4732-47	5.6	21
81	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
80	Mammary fibroblasts regulate morphogenesis of normal and tumorigenic breast epithelial cells by mechanical and paracrine signals. *Cancer Letters*, **2012**, 325, 175-88	9.9	20
79	A nonsynonymous polymorphism in IRS1 modifies risk of developing breast and ovarian cancers in BRCA1 and ovarian cancer in BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 1362-70	4	20
78	The prognostic and predictive value of immunohistochemically detected HER-2/neu overexpression in 361 patients with ovarian cancer: a multicenter study. *Gynecologic Oncology*, **2004**, 95, 89-94	4.9	20
77	Quantifying cell free DNA in urine: comparison between commercial kits, impact of gender and inter-individual variation. *BioTechniques*, **2018**, 64, 225-230	2.5	20
76	High resolution copy number analysis of IRF4 translocation-positive diffuse large B-cell and follicular lymphomas. *Genes Chromosomes and Cancer*, **2013**, 52, 150-5	5	19
75	Combined treatment with TRAIL and PPAR□ligands overcomes chemoresistance of ovarian cancer cell lines. *Journal of Cancer Research and Clinical Oncology*, **2011**, 137, 875-86	4.9	19
74	Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition. *Cancer Genetics and Cytogenetics*, **2009**, 192, 44-7		19
73	A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. *Auris Nasus Larynx*, **2004**, 31, 149-53	2.2	19
72	The impact of electrical charge on the viability and physiology of dendritic cells. *Scandinavian Journal of Immunology*, **2005**, 62, 399-406	3.4	19
71	The CpG island methylator phenotype in breast cancer is associated with the lobular subtype. *Epigenomics*, **2015**, 7, 187-99	4.4	18
70	Identification of a DMBT1 polymorphism associated with increased breast cancer risk and decreased promoter activity. *Human Mutation*, **2010**, 31, 60-6	4.7	18

69	Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance. *International Journal of Cancer*, **2020**, 146, 999-1009	7.5	18
68	The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2009**, 101, 1456-60	8.7	17
67	Establishing a control population to screen for the occurrence of nineteen unclassified variants in the BRCA1 gene by denaturing high-performance liquid chromatography. *Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences*, **2002**, 782, 99-104	3.2	17
66	Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors. *Journal of Leukocyte Biology*, **2020**, 107, 1081-1095	6.5	17
65	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
64	Genetic variants within miR-126 and miR-335 are not associated with breast cancer risk. *Breast Cancer Research and Treatment*, **2011**, 127, 549-54	4.4	16
63	Array-CGH analysis of microdissected chromosome 19 markers in ovarian carcinoma identifies candidate target genes. *Genes Chromosomes and Cancer*, **2010**, 49, 1046-53	5	16
62	Highly comprehensive karyotype analysis by a combination of spectral karyotyping (SKY), microdissection, and reverse painting (SKY-MD). *Chromosome Research*, **2001**, 9, 395-402	4.4	16
61	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
60	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
59	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
58	Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *British Journal of Cancer*, **2009**, 101, 2048-54	8.7	13
57	Recurrent loss of the Y chromosome and homozygous deletions within the pseudoautosomal region 1: association with male predominance in mantle cell lymphoma. *Haematologica*, **2008**, 93, 949-50	6.6	13
56	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
55	Combination of enzastaurin and pemetrexed inhibits cell growth and induces apoptosis of chemoresistant ovarian cancer cells regulating extracellular signal-regulated kinase 1/2 phosphorylation. *Translational Oncology*, **2009**, 2, 164-73	4.9	12
54	An evaluation of the polymorphisms Ins16bp and Arg72Pro in p53 as breast cancer risk modifiers in BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2008**, 99, 974-7	8.7	12
53	Comparison of comparative genomic hybridization and interphase fluorescence in situ hybridization in ovarian carcinomas: possibilities and limitations of both techniques. *Cancer Genetics and Cytogenetics*, **2000**, 122, 7-12		12
52	Spectrum of genetic variants of BRCA1 and BRCA2 in a German single center study. *Archives of Gynecology and Obstetrics*, **2017**, 295, 1227-1238	2.5	11

51	A variant affecting miRNAs binding in the circadian gene Neuronal PAS domain protein 2 (NPAS2) is not associated with breast cancer risk. *Breast Cancer Research and Treatment*, **2011**, 127, 769-75	4.4	11
50	Coincident PTCH and BRCA1 germline mutations in a patient with nevoid basal cell carcinoma syndrome and familial breast cancer. *Journal of Investigative Dermatology*, **2001**, 116, 472-4	4.3	11
49	Ten novel BRCA1 and BRCA2 mutations in breast and/or ovarian cancer families from northern Germany. *Human Mutation*, **2000**, 16, 529-30	4.7	11
48	ADAM17 inhibition enhances platinum efficiency in ovarian cancer. *Oncotarget*, **2018**, 9, 16043-16058	3.3	11
47	SNiPER: a novel hypermethylation biomarker panel for liquid biopsy based early breast cancer detection. *Oncotarget*, **2019**, 10, 6494-6508	3.3	11
46	Evaluation of potentially predictive markers for anti-angiogenic therapy with sunitinib in recurrent ovarian cancer patients. *Translational Oncology*, **2013**, 6, 305-10	4.9	10
45	Prognostic value of human epidermal growth factor receptor 2 (Her-2)/neu in patients with advanced ovarian cancer treated with platinum/paclitaxel as first-line chemotherapy: a retrospective evaluation of the AGO-OVAR 3 Trial by the AGO OVAR Germany. *International Journal of Gynecological Cancer*, **2009**, 19, 109-15	3.5	10
44	Metastatic triple-negative breast cancer patient with tumor mutation experienced 11 months progression-free survival on bortezomib monotherapy without adverse events after ending standard treatments with grade 3 adverse events. *Journal of Physical Education and Sports Management*, **2017**, 3,	2.8	9
43	Association of death receptor 4 variant (683A > C) with ovarian cancer risk in BRCA1 mutation carriers. *International Journal of Cancer*, **2012**, 130, 1314-8	7.5	9
42	Aurora kinase inhibitor AZD1152 has an additional effect of platinum on a sequential application at the human ovarian cancer cell line SKOV3. *Archives of Gynecology and Obstetrics*, **2013**, 288, 173-82	2.5	9
41	Nuclear receptor coregulator SNP discovery and impact on breast cancer risk. *BMC Cancer*, **2009**, 9, 438	4.8	9
40	Strong evidence that the common variant S384F in BRCA2 has no pathogenic relevance in hereditary breast cancer. *Breast Cancer Research*, **2005**, 7, R775-9	8.3	9
39	Proof of partial imbalances 6q and 11q due to maternal complex balanced translocation analyzed by microdissection of multicolor labeled chromosomes (FISH-MD) in a patient with Dandy-Walker variant. *Cytogenetic and Genome Research*, **2006**, 114, 235-9	1.9	9
38	CDH1 mutation screen in a BRCA1/2-negative familial breast-/ovarian cancer cohort. *Archives of Gynecology and Obstetrics*, **2018**, 297, 147-152	2.5	8
37	Isolated trisomy 7q21.2-31.31 resulting from a complex familial rearrangement involving chromosomes 7, 9 and 10. *Molecular Cytogenetics*, **2011**, 4, 28	2	7
36	A network of clinically and functionally relevant genes is involved in the reversion of the tumorigenic phenotype of MDA-MB-231 breast cancer cells after transfer of human chromosome 8. *Oncogene*, **2005**, 24, 869-79	9.2	7
35	Criteria of the German Consortium for Hereditary Breast and Ovarian Cancer for the Classification of Germline Sequence Variants in Risk Genes for Hereditary Breast and Ovarian Cancer. *Geburtshilfe Und Frauenheilkunde*, **2020**, 80, 410-429	2	6
34	Changes in classification of genetic variants in BRCA1 and BRCA2. *Archives of Gynecology and Obstetrics*, **2018**, 297, 279-280	2.5	6

33	Alteration of STR profiles in ovarian carcinoma cells during primary culture. *Archives of Gynecology and Obstetrics*, **2016**, 294, 369-76	2.5	6
32	Polymorphisms in BRCA2 resulting in aberrant codon-usage and their analysis on familial breast cancer risk. *Breast Cancer Research and Treatment*, **2009**, 118, 407-13	4.4	6
31	Chromosomal mosaicisms in prenatal diagnosis: correlation with first trimester screening and clinical outcome. *Journal of Perinatal Medicine*, **2012**, 40, 215-23	2.7	6
30	Breakpoint characterization of the der(19)t(11;19)(q13;p13) in the ovarian cancer cell line SKOV-3. *Genes Chromosomes and Cancer*, **2013**, 52, 512-22	5	5
29	Characterization of two supernumerary marker chromosomes in a patient with signs of Klinefelter syndrome, mild facial anomalies, and severe speech delay. *American Journal of Medical Genetics, Part A*, **2006**, 140, 488-95	2.5	5
28	Simultaneous congener-specific determination of selected organochlorine compounds and nitro musks in human whole blood samples by solid-phase extraction and capillary gas chromatography with electron capture detection. *Journal of Analytical Toxicology*, **2005**, 29, 110-7	2.9	5
27	Linking pre-existing biorepositories for medical research: the PopGen 2.0 Network. *Journal of Community Genetics*, **2019**, 10, 523-530	2.5	4
26	Oocyte morphology on day 0 correlates with aneuploidy as detected by polar body biopsy and FISH. *Archives of Gynecology and Obstetrics*, **2014**, 289, 445-50	2.5	4
25	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2021**, 113, 893-899	9.7	4
24	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
23	Head-to-head comparison of the impact of Aurora A, Aurora B, Repp86, CDK1, CDK2 and Ki67 expression in two of the most relevant gynaecological tumor entities. *Archives of Gynecology and Obstetrics*, **2016**, 294, 813-23	2.5	3
22	Investigating the effects of additional truncating variants in DNA-repair genes on breast cancer risk in BRCA1-positive women. *BMC Cancer*, **2019**, 19, 787	4.8	3
21	Frequent translocations of 11q13.2 and 19p13.2 in ovarian cancer. *Genes Chromosomes and Cancer*, **2014**, 53, 447-53	5	3
20	Allelic loss analysis by denaturing high-performance liquid chromatography and electrospray ionization mass spectrometry. *Human Mutation*, **2007**, 28, 303-11	4.7	3
19	Gene Expression Profiling of Epithelial Ovarian Cancer. *Current Genomics*, **2006**, 7, 115-135	2.6	3
18	Premature ovarian failure in a patient with a complex chromosome rearrangement involving the critical region Xq24, characterized by analysis using fluorescence in situ hybridization by chromosome microdissection. *Fertility and Sterility*, **2007**, 88, 1677.e9-13	4.8	3
17	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
16	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. *Scientific Reports*, **2020**, 10, 9688	4.9	2

15	Sham-controlled implantation after preimplantation genetic screening by polar body biopsy and FISH. *Archives of Gynecology and Obstetrics*, **2014**, 289, 439-44	2.5	2
14	Translationale Forschung in der gynäkologischen Onkologie: Serum-Tumormarker zur Früherkennung des Ovarialkarzinoms. *Geburtshilfe Und Frauenheilkunde*, **2008**, 68, 830-837	2	2
13	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
12	BRCA1/2 mutation prevalence in triple-negative breast cancer patients without family history of breast and ovarian cancer.. *Journal of Clinical Oncology*, **2016**, 34, 1090-1090	2.2	1
11	ADAM17-A Potential Blood-Based Biomarker for Detection of Early-Stage Ovarian Cancer. *Cancers*, **2021**, 13,	6.6	1
10	The GPRC5A frameshift variant c.183del is not associated with increased breast cancer risk in BRCA1 mutation carriers. *International Journal of Cancer*, **2019**, 144, 1761-1763	7.5	1
9	RNA based individualized drug selection in breast cancer patients without patient-matched normal tissue. *Oncotarget*, **2018**, 9, 32362-32372	3.3	1
8	Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation **2001**, 91, 534		1
7	Asservierung von Biomaterialien für translationale Fragestellungen im Rahmen aktueller Brustkrebsstudien. Überblick und Empfehlungen. *Geburtshilfe Und Frauenheilkunde*, **2007**, 67, 451-459	2	0
6	Aktualisierte Kriterien des Deutschen Konsortiums Familiärer Brust- und Eierstockkrebs zur Klassifizierung von Keimbahn-Sequenzvarianten in Risikogenen für familiären Brust- und Eierstockkrebs. *Senologie - Zeitschrift Für Mammadiagnostik Und -therapie*, **2021**, 18, 136-162	0	0
5	Reply to letter by Dr. G. Corso. *Archives of Gynecology and Obstetrics*, **2018**, 297, 1069	2.5	
4	Personalisierte Medizin bei soliden Tumoren. *Medizinische Genetik*, **2016**, 28, 443-451	0.5	
3	Hereditäres Ovarialkarzinom. *Onkologe*, **2008**, 14, 1120-1129	0.1	
2	An Activating Mutation (Ser525Pro) within the Transactivation Domain of REL in Two Patients with Human B-Cell Lymphomas Enhances RELs In Vitro Transforming Activity.. *Blood*, **2005**, 106, 2617-2617	2.2	
1	NGS-based multi-gene panel analysis in BRCA1/2-negative breast and ovarian cancer families.. *Journal of Clinical Oncology*, **2017**, 35, 1526-1526	2.2	